Key result
Isosorbide dinitrate therapy for severe congestive heart failure reduced morbid events (7 vs 17 events) and significantly increased maximal exercise duration by 2.54 minutes compared with placebo.
Why the study?
Does isosorbide dinitrate improve outcomes and symptoms in patients with severe congestive heart failure?
RCT (n=16)
Double-blind
Crossover
Does isosorbide dinitrate improve outcomes and symptoms in patients with severe congestive heart failure?
Absolute Event Rate: 8.2% vs 22.4%
Isosorbide dinitrate added to standard therapy reduces morbid events and improves exercise duration in patients with severe congestive heart failure.
Supports adding isosorbide dinitrate to standard therapy in severe CHF; extends RCT evidence for nitrate benefit on morbidity and exercise.
A randomized double-blind crossover trial included 16 patients with severe congestive heart failure who received isosorbide dinitrate or placebo for eight weeks, and then the opposite treatment for eight more weeks. All patients received their usual maintenance therapy with digitalis and diuretics. Seven morbid events occurred during 85 patient-weeks of isosorbide dinitrate therapy compared with 17 during 76 patient-weeks of placebo. Severity of congestive heart failure improved in all eight patients who received isosorbide dinitrate compared with two patients who showed improvement and five whose symptoms became worse with placebo. No significant differences in physical findings, cardiac dimensions, or resting hemodynamics were observed. Maximal exercise duration increased significantly by 2.54 minutes with isosorbide dinitrate therapy, and rose insignificantly by 1.24 minutes with placebo. This preliminary trial suggests that long-term vasodilator therapy may be clinically beneficial in congestive heart failure. (JAMA240:443-446, 1978)
No takes yet. Share an insight, caveat, or question.
Joseph A. Franciosa (1978) conducted an RCT in Severe congestive heart failure (n=16). Isosorbide dinitrate vs. Placebo was evaluated on Morbid events. Isosorbide dinitrate therapy for severe congestive heart failure reduced morbid events (7 vs 17 events) and significantly increased maximal exercise duration by 2.54 minutes compared with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: